An IDH1 mutation is a genetic change in the IDH1 gene that alters how cells process energy, causing a buildup of an abnormal molecule that can drive cancer growth. It’s found in more than 75% of low-grade brain tumors (gliomas), about 20% of acute myeloid leukemia cases, and several other cancer types. If you’ve seen this term on a pathology report, it’s actually one of the more favorable molecular markers in brain cancer, and it now directly shapes both diagnosis and treatment.
What the IDH1 Gene Normally Does
The IDH1 gene provides instructions for making an enzyme called isocitrate dehydrogenase 1, which sits in the cell’s cytoplasm and plays a role in metabolism. Under normal conditions, this enzyme converts a molecule called isocitrate into another called alpha-ketoglutarate as part of the cell’s energy-producing cycle. A key byproduct of this reaction is NADPH, a molecule cells use to neutralize harmful free radicals and protect against oxidative damage. In short, the normal IDH1 enzyme helps cells both generate energy and defend themselves.
How the Mutation Changes Cell Behavior
When IDH1 is mutated, the enzyme loses its normal function and gains a new, harmful one. Instead of producing alpha-ketoglutarate, the mutant enzyme converts it into a different molecule: D-2-hydroxyglutarate (D-2HG). This molecule accumulates to abnormally high levels inside the cell, where it interferes with enzymes that regulate gene expression.
The most common IDH1 mutation, called R132H, accounts for about 90% of cases. It involves a single amino acid swap at position 132 of the protein. The result is widespread: D-2HG disrupts the chemical tags on DNA that control which genes are turned on or off. This causes a pattern of abnormal DNA methylation that locks cells in an immature state, preventing them from developing normally and promoting tumor formation. The mutation essentially reprograms the cell’s identity at the epigenetic level.
Which Cancers Carry IDH1 Mutations
IDH1 and its closely related gene IDH2 are the most frequently mutated metabolic genes in human cancer. They appear across a range of tumor types, though at very different rates:
- Low-grade gliomas and secondary glioblastoma: more than 75%
- Chondrosarcoma (a bone cancer): about 56%
- Acute myeloid leukemia (AML): roughly 20%
- Intrahepatic cholangiocarcinoma (bile duct cancer): approximately 9-10%
- Melanoma: around 10%
The mutation also appears in over 80% of two rare bone conditions, Ollier disease and Maffucci syndrome, both of which carry an elevated risk of developing into cancer.
Why It Matters for Brain Tumor Diagnosis
IDH1 mutation status has become one of the most important markers in brain tumor classification. The 2021 WHO Classification of Central Nervous System Tumours reorganized adult brain tumors around molecular features rather than just how cells look under a microscope. Adult diffuse gliomas now fall into just three categories: astrocytoma with an IDH mutation, oligodendroglioma with an IDH mutation (plus a specific chromosomal change called 1p/19q codeletion), and glioblastoma without an IDH mutation (called IDH-wildtype).
This means the presence or absence of an IDH mutation can determine your diagnosis entirely. A diffuse brain tumor without an IDH mutation is classified as glioblastoma, the most aggressive type, regardless of how the cells appear on a slide. Meanwhile, IDH-mutant astrocytomas are graded from 2 to 4 based on other features, but they are all considered a single disease type that behaves differently from IDH-wildtype tumors. Any IDH-mutant glioma also gets tested for 1p/19q codeletion, because finding both changes means the tumor is an oligodendroglioma, even if it looks like an astrocytoma under the microscope.
IDH1 Mutation and Prognosis
Having an IDH1 mutation in a brain tumor is associated with significantly better outcomes. In glioblastoma, patients with IDH-mutant tumors survive a median of about 31 months, compared to roughly 15 months for those with IDH-wildtype tumors. That’s more than double the survival time. For lower-grade gliomas (grade 2 and 3), the presence of an IDH mutation similarly predicts a slower-growing, more treatment-responsive disease. This is why the 2021 WHO reclassification was so meaningful: separating tumors by IDH status gives patients and their doctors a much clearer picture of what to expect.
How IDH1 Mutations Are Tested
Testing for IDH1 mutations typically starts with immunohistochemistry (IHC), a staining technique performed on tumor tissue. A specific antibody can detect the R132H variant, which is the most common mutation. This initial test agrees with genetic sequencing results 88% to 99% of the time.
When IHC comes back negative, many centers follow up with DNA sequencing to check for rarer IDH1 variants (such as R132C, R132L, R132S, and R132G) and IDH2 mutations that the staining test cannot detect. These less common variants each account for only 1-4% of cases, but missing them could lead to an incorrect diagnosis. This two-step approach, staining first and sequencing when needed, has become standard practice at most major cancer centers.
Targeted Treatments for IDH1-Mutant Cancers
Because the mutant IDH1 enzyme produces a specific abnormal molecule, it’s a natural drug target. Several therapies now block the mutant enzyme directly, reducing D-2HG levels and, in some cases, allowing cancer cells to mature and stop dividing.
For acute myeloid leukemia, two IDH1 inhibitors have received FDA approval. Ivosidenib was the first, and olutasidenib (brand name Rezlidhia) was approved in December 2022 for adults with relapsed or refractory AML carrying a susceptible IDH1 mutation.
The most significant recent development came in August 2024, when the FDA approved vorasidenib (brand name Voranigo) for grade 2 astrocytoma or oligodendroglioma with an IDH1 or IDH2 mutation. This was the first systemic therapy ever approved for these low-grade brain tumors. In the clinical trial that led to approval, 331 patients were randomized to receive vorasidenib or a placebo after surgery. Vorasidenib reduced the risk of disease progression by 61%, and patients on the drug went significantly longer before needing additional surgery or other treatment. The median time to next intervention wasn’t even reached in the vorasidenib group, compared to 17.8 months on placebo. The drug is taken as a daily pill, making it a practical option for patients who previously had few choices beyond surgery and monitoring.
For patients 12 and older weighing at least 40 kg, the standard dose is 40 mg once daily, with a lower dose for smaller patients. Treatment continues until the disease progresses or side effects become unacceptable.